Helsinki, Finland – February 2025 – MVision AI announces the introduction of Dose+, a software medical device designed to assist radiation therapy professionals in treatment planning through AI-powered dose prediction. Initially validated for prostate and pelvic lymph node cases, Dose+ provides radiation therapy professionals with patient-specific dose predictions to facilitate the optimization process.
Dose+ addresses a recognized challenge in radiation therapy planning: balancing standardization with patient-specific anatomical variations. The software analyzes CT images and associated structure sets to generate achievable dose predictions based on individual patient geometry, providing qualified medical professionals with additional information to guide the optimization process.
Clinical validation studies conducted across several healthcare institutions in Europe and North America have demonstrated significant efficiency gains in the treatment planning process while maintaining non-inferior plan quality compared to conventional approaches. The studies showed that AI-guided planning resulted in more consistent outcomes across different planners and treatment planning systems, helping radiation therapy departments standardize their planning workflows without compromising established quality standards.
Integration has been validated with major commercial treatment planning systems through standard DICOM protocols. This vendor-neutral approach allows a smooth integration into existing and established clinical workflows.
The introduction of Dose+ marks an important milestone in our mission to enhance radiation therapy workflows through AI innovation,
said Saad Ullah Akram, CEO of MVision AI.
Building on the success of our Contour+ AI segmentation service, Dose+ further demonstrates our commitment to developing practical solutions that enable clinicians to spend more time focusing on patient care while maintaining the highest standards of treatment quality.
About MVision AI
MVision AI is a leading provider of AI-powered solutions for radiation therapy treatment planning. Our mission is to empower Radiation Oncology professionals with cutting-edge technology to streamline and standardize workflows, enhance treatment quality, and facilitate more patient-focused care. With a commitment to innovation and excellence, MVision AI continues to advance cancer care through the power of AI.
Regulatory Notice
Dose+ is designed for use by qualified radiation therapy professionals. All dose predictions require review and validation by qualified professionals before clinical use. The software serves as a planning aid and is not intended to trigger treatment decisions.
Dose+ is not available for sale in all markets and 510(k) pending in the United States. Check with your local MVision AI representative regarding availability in your region.
